Swamped with your writing assignments? Take the weight off your shoulder!
The Diagnostics Assessment Programme (DAP) evaluates diagnostic technologies using cost-effectiveness analysis but it differs in various significant ways from the Technology Appraisal Programme, which also uses cost-effectiveness analysis. The differences are outlined below:
1) Evidence about patient outcomes for diagnostic technologies is typically lower in quantity and quality than evidence for pharmaceutical products.
2) Because most benefit to the patient arises from treatment based on the result of the diagnostic test, the value of the test or technology is best understood in the context of its effect on the pathway of care.
3) Diagnostic technologies, particularly those based on electronics, often change rapidly as new methods, upgrades and capabilities are added.
4) It is often not obvious where in the care pathway the diagnostic technology is best placed, so different options are evaluated.
Using the attached documents and other possible resources write 1000 words about the methodology to evaluate both The Diagnostics Assessment Programme and the Technology Appraisal Programme